A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
RCT (n=66) reports dapagliflozin significantly reduced left ventricular mass (LVM) vs. placebo with absolute mean change of −2.82g [95% CI: −5.13 to −0.51, P=0.018], suggesting dapagliflozin can initiate reverse remodelling which may contribute to its cardio-protective effects.
Source:
European Heart Journal
SPS commentary:
Authors’ of a related editorial highlight this reduction in LVM was accompanied by reductions in systolic BP, body weight, visceral adipose tissue and subcutaneous adipose tissue, insulin resistance, and high-sensitivity C-reactive protein; which may contribute to the cardio-protective effects of dapagliflozin.